ReNeuron Group plc Key patent grants expand exosome IP portfolio (6496F)

TIDMRENE

RNS Number : 6496F

ReNeuron Group plc

16 July 2019

 
 16 July 2019   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

Key patent grants expand exosome IP portfolio

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has expanded its intellectual property estate via the grant of a number of key patents covering its exosome technology platform.

New patents have recently issued covering ReNeuron's neural stem cell-derived exosomes and their methods of production. Patents granted in China (CN 104321062 B and CN 104703609 B), Korea (KR 10-1993027), Japan (JP 6450673) and Europe (EP2833893 and EP2877187) include claims to: (i) a method of producing exosomes derived from differentiated stem cells; (ii) methods of production; and (iii) composition of matter for exosomes derived from the Company's CTX neural stem cells.

A further patent has issued in Japan (JP 6491661) with claims including use of a neural stem cell exosome in the treatment of glioma (brain cancer).

ReNeuron is targeting its exosome technology programme towards value-generating business partnerships in which its exosomes may be exploited as a novel vector for delivering third party biological drugs.

Following these patent grants, ReNeuron's patent estate consists of over 40 patents worldwide covering its cell-based therapies and exosome technology.

Olav Hellebø, Chief Executive Officer of ReNeuron, commented:

"We are pleased to have received these recent patent grants relating to our exosome technology platform. We expect to build this patent estate further in the near future. The recent and expected grants will stand us in good stead as we seek valuable collaboration deals to exploit ReNeuron's exosome platform as a novel system for delivering advanced therapeutics such as gene therapies."

ENDS

ENQUIRIES:

 
ReNeuron                                                                         [phone] 
Olav Hellebø, Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
 
  Buchanan (UK)                                                                 [phone] 
Mark Court, Sophie Wills, Tilly Abraham 
 
  Argot Partners (US)                                                                [phone] 
  Stephanie Marks, Claudia Styslinger 
 
  Stifel Nicolaus Europe Limited                                                [phone] 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) 
 
  N+1 Singer                                                                    [phone] 
Aubrey Powell, James Moat, Iqra Amin 
 (Joint Broker) 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCSFLSIMFUSEEW

(END) Dow Jones Newswires

July 16, 2019 02:00 ET (06:00 GMT)